Genentech

January 18, 2016January 19, 2016

Drug’s Safety for Idiopathic Pulmonary Fibrosis Supported by 5 Clinical Trials

Research from an international, collaborative group of scientists, led by researchers at Vanderbilt University in Tennessee, supports the safety of pirfenidone as a therapy for idiopathic pulmonary fibrosis (IPF). The ... Read more

December 14, 2015December 14, 2015

FDA Approves Genentech’s ALECENSA as Oral Therapy for Advanced ALK-positive Non-small Cell Lung Cancer

Lung Cancer, News

ALECENSA (alectinib), a therapy commercialized by Genentech, was approved by U.S. Food and Drug Administration for the treatment of patients with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) previously ... Read more

November 30, 2015November 30, 2015

Mid-summer Asthma Treatment May Help Prevent Fall Flare-ups

Asthma, News

A study shows that omalizumab (Xolair®, Genentech, Novartis) used in combination with standard care four to six weeks before the start of the school year helps to prevent asthma exacerbations in inner-city children and ... Read more

August 13, 2015November 5, 2015

American Thoracic Society Recommends Esbriet (Pirfenidone) in Updated IPF Treatment Guidelines

Idiopathic Pulmonary Fibrosis, News

Esbriet (pirfenidone) by Genentech was recently included in the American Thoracic Society’s (ATS) updated idiopathic pulmonary fibrosis (IPF) treatment guidelines, which presents the drug’s proven benefits in delaying disease progression, as determined ... Read more

March 3, 2015November 9, 2015

Genentech to Present at 2015 COPD & Asthma Conference on Biomarker Selection

COPD, News

Biotechnology company Genentech has been invited to present at the 11th Asthma & COPD conference, an annual event that will gather some of the most internationally prominent scientists, clinicians and industry leaders to discuss ... Read more